The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation

Nucleic Acid Therapeutics

Volumn 22, Issue 4, 2012, Pages 283-288

  Rizzo, Milena ^a   Mariani, Laura ^a   Cavallini, Sara ^a   Simili, Marcella ^a   Rainaldi, Giuseppe ^a,b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; MICRORNA 34A; MYC PROTEIN; NUTLIN 3; PROTEIN P53; SMALL INTERFERING RNA;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FOLLICULAR LYMPHOMA; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; LYMPHOMA CELL LINE; PRIORITY JOURNAL; UPREGULATION;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOWN-REGULATION; ETOPOSIDE; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HUMANS; IMIDAZOLES; LYMPHOMA; MICRORNAS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865441721     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0343     Document Type: Article

References (19)

1. CHEN, L., IRACI, N., GHERARDI, S., GAMBLE, L.D., WOOD, K.M., PERINI, G., LUNEC, J., and TWEDDLE, D.A. (2010). p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res. 70, 1377-1388.
2. CHRISTOFFERSEN, N.R., SHALGI, R., FRANKEL, L.B., LEUCCI, E., LEES, M., KLAUSEN, M., PILPEL, Y., NIELSEN, F.C., OREN, M., and LUND, A.H. (2010). p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 17, 236-245.
3. CUMMINS, J.M., HE, Y., LEARY, R.J., PAGLIARINI, R., DIAZ, L.A., JR., SJOBLOM, T., BARAD, O., BENTWICH, Z., SZAFRANSKA,A.E.,LABOURIER,E., et al. (2006). The colorectal microRNAome. Proc. Natl. Acad. Sci. U. S. A. 103, 3687-3692. (Pubitemid 43376616)
4. DYER, M.J., LILLINGTON, D.M., BASTARD, C., TILLY, H., LENS, D., HEWARD, J.M., STRANKS, G., MORILLA, R., MONRAD, S., GUGLIELMI, P., et al. (1996). Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus. Leukemia 10, 1198-1208. (Pubitemid 26254026)
5. GARTEL, A.L., and TYNER, A.L. (1999). Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp. Cell Res. 246, 280-289. (Pubitemid 29393989)
6. GARZON, R., MARCUCCI, G., and CROCE, C.M. (2010). Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775-789.
7. HE, L., HE, X., LIM, L.P., DE STANCHINA, E., XUAN, Z., LIANG, Y., XUE, W., ZENDER, L., MAGNUS, J., RIDZON, D., et al. (2007). A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134. (Pubitemid 47014436)
8. HERMEKING, H. (2010). The miR-34 family in cancer and apoptosis. Cell Death Differ. 17, 193-199.
9. KNOOPS, L., HAAS, R., DE KEMP, S., MAJOOR, D., BROEKS, A., ELDERING, E., DE BOER, J.P., VERHEIJ, M., VAN OSTROM, C., DE VRIES, A., et al. (2007). In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 110, 1116-1122. (Pubitemid 47281406)
10. LEICH, E., OTT, G., and ROSENWALD, A. (2011). Pathology, pathogenesis and molecular genetics of follicular NHL. Best Pract. Res. Clin. Haematol. 24, 95-109.
11. PHAN, R.T., and DALLA-FAVERA, R. (2004). The BCL6 protooncogene suppresses p53 expression in germinal-centre B cells. Nature 432, 635-639. (Pubitemid 39626271)
12. PHAN, R.T., SAITO, M., BASSO, K., NIU, H., and DALLAFAVERA, R. (2005). BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat. Immunol. 6, 1054-1060. (Pubitemid 41486191)
13. PHAN, R.T., SAITO, M., KITAGAWA, Y., MEANS, A.R., and DALLA-FAVERA, R. (2007). Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells. Nat. Immunol. 8, 1132-1139. (Pubitemid 47423761)
14. POLISENO, L., PITTO, L., SIMILI, M., MARIANI, L., RICCARDI, L., CIUCCI, A., RIZZO, M., EVANGELISTA, M.,MERCATANTI, A., PANDOLFI, P.P. and RAINALDI, G. (2008). The proto-oncogene LRF is under post-transcriptional control of MiR-20a: implications for senescence. PLoS One 3, e2542.
15. SAHA, M.N., MICALLEF, J., QIU, L., and CHANG, H. (2010). Pharmacological activation of the p53 pathway in haematological malignancies. J. Clin. Pathol. 63, 204-209.
16. SECCHIERO, P., BOSCO, R., CELEGHINI, C., and ZAULI, G. (2011). Recent advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des. 17, 569-577.
17. SHEN, H., and MAKI, C.G. (2011). Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr. Pharm. Des.17, 560-8.
18. SOTILLO, E., LAVER, T., MELLERT, H., SCHELTER, J.M., CLEARY, M.A., MCMAHON, S., and THOMAS-TIKHONENKO, A. (2011). Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 30, 2587-2594.
19. VASSILEV, L.T., VU, B.T., GRAVES, B., CARVAJAL, D., PODLASKI, F., FILIPOVIC, Z., KONG, N., KAMMLOTT, U., LUKACS, C., KLEIN, C., et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848. (Pubitemid 38174664)